Bank of America’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-45
| Closed | -$301 | – | 6224 |
|
|
2025
Q4 | $301 | Buy |
45
+1
| +2% | +$6 | ﹤0.01% | 6639 |
|
|
2025
Q3 | $193 | Sell |
44
-611
| -93% | -$2.9K | ﹤0.01% | 7739 |
|
|
2025
Q2 | $2.9K | Sell |
655
-1,774
| -73% | -$7.41K | ﹤0.01% | 7374 |
|
|
2025
Q1 | $13.7K | Sell |
2,429
-1,459
| -38% | -$18.7K | ﹤0.01% | 7049 |
|
|
2024
Q4 | $82K | Buy |
3,888
+1,194
| +44% | +$27.4K | ﹤0.01% | 6477 |
|
|
2024
Q3 | $72.5K | Buy |
2,694
+107
| +4% | +$3.15K | ﹤0.01% | 6447 |
|
|
2024
Q2 | $73.7K | Buy |
2,587
+1,544
| +148% | +$54.2K | ﹤0.01% | 6387 |
|
|
2024
Q1 | $44.2K | Sell |
1,043
-2,485
| -70% | -$112K | ﹤0.01% | 6561 |
|
|
2023
Q4 | $189K | Buy |
3,528
+1,712
| +94% | +$77.3K | ﹤0.01% | 6094 |
|
|
2023
Q3 | $78.1K | Buy |
1,816
+924
| +104% | +$42.6K | ﹤0.01% | 6354 |
|
|
2023
Q2 | $49K | Sell |
892
-2,720
| -75% | -$149K | ﹤0.01% | 6472 |
|
|
2023
Q1 | $152K | Buy |
3,612
+2,724
| +307% | +$80.8K | ﹤0.01% | 6056 |
|
|
2022
Q4 | $24.6K | Buy |
888
+35
| +4% | +$863 | ﹤0.01% | 6676 |
|
|
2022
Q3 | $22K | Buy |
853
+750
| +728% | +$24.8K | ﹤0.01% | 6993 |
|
|
2022
Q2 | $3K | Sell |
103
-2,473
| -96% | -$112K | ﹤0.01% | 7710 |
|
|
2022
Q1 | $160K | Buy |
2,576
+798
| +45% | +$47.2K | ﹤0.01% | 6602 |
|
|
2021
Q4 | $125K | Buy |
1,778
+1,051
| +145% | +$74.7K | ﹤0.01% | 6768 |
|
|
2021
Q3 | $51K | Buy |
727
+19
| +3% | +$1.51K | ﹤0.01% | 7030 |
|
|
2021
Q2 | $59K | Sell |
708
-3,967
| -85% | -$281K | ﹤0.01% | 6754 |
|
|
2021
Q1 | $255K | Buy |
4,675
+3,276
| +234% | +$159K | ﹤0.01% | 5861 |
|
|
2020
Q4 | $60K | Buy |
1,399
+1,235
| +753% | +$46.1K | ﹤0.01% | 6248 |
|
|
2020
Q3 | $5K | Sell |
164
-590
| -78% | -$19.8K | ﹤0.01% | 6581 |
|
|
2020
Q2 | $24K | Buy |
+754
| New | +$20.3K | ﹤0.01% | 6217 |
|
|
2019
Q4 | – | Sell |
-30
| Closed | -$1K | – | 7206 |
|
|
2019
Q3 | $1K | Sell |
30
-6,786
| -100% | -$169K | ﹤0.01% | 7106 |
|
|
2019
Q2 | $136K | Sell |
6,816
-42,361
| -86% | -$1.24M | ﹤0.01% | 5836 |
|
|
2019
Q1 | $2.12M | Buy |
49,177
+40,913
| +495% | +$1.48M | ﹤0.01% | 3944 |
|
|
2018
Q4 | $262K | Buy |
8,264
+583
| +8% | +$23K | ﹤0.01% | 5349 |
|
|
2018
Q3 | $403K | Sell |
7,681
-7,026
| -48% | -$394K | ﹤0.01% | 5101 |
|
|
2018
Q2 | $787K | Sell |
14,707
-91
| -0.6% | -$4.66K | ﹤0.01% | 4627 |
|
|
2018
Q1 | $740K | Buy |
14,798
+659
| +5% | +$29.5K | ﹤0.01% | 4576 |
|
|
2017
Q4 | $467K | Hold |
14,139
| – | – | ﹤0.01% | 4986 |
|
|
2017
Q3 | $530K | Hold |
14,139
| – | – | ﹤0.01% | 4912 |
|
|
2017
Q2 | $361K | Buy |
14,139
+4,148
| +42% | +$103K | ﹤0.01% | 5057 |
|
|
2017
Q1 | $260K | Sell |
9,991
-17
| -0.2% | -$490 | ﹤0.01% | 5202 |
|
|
2016
Q4 | $305K | Buy |
10,008
+13
| +0.1% | +$331 | ﹤0.01% | 5108 |
|
|
2016
Q3 | $272K | Sell |
9,995
-1,334
| -12% | -$37K | ﹤0.01% | 4976 |
|
|
2016
Q2 | $324K | Buy |
11,329
+1,338
| +13% | +$42.6K | ﹤0.01% | 4947 |
|
|
2016
Q1 | $302K | Sell |
9,991
-181
| -2% | -$5.13K | ﹤0.01% | 4906 |
|
|
2015
Q4 | $352K | Buy |
10,172
+10,116
| +18,064% | +$346K | ﹤0.01% | 5028 |
|
|
2015
Q3 | $2K | Sell |
56
-145
| -72% | -$6.75K | ﹤0.01% | 6965 |
|
|
2015
Q2 | $11K | Buy |
+201
| New | +$11.4K | ﹤0.01% | 6556 |
|
|
2014
Q3 | – | Sell |
-6,439
| Closed | -$293K | – | 8067 |
|
|
2014
Q2 | $293K | Buy |
6,439
+6,434
| +128,680% | +$270K | ﹤0.01% | 5162 |
|
|
2014
Q1 | $0 | Sell |
5
-15
| -75% | -$683 | ﹤0.01% | 7911 |
|
|
2013
Q4 | $1K | Sell |
20
-175
| -90% | -$7.64K | ﹤0.01% | 7730 |
|
|
2013
Q3 | $8K | Sell |
195
-1,671
| -90% | -$65.7K | ﹤0.01% | 7240 |
|
|
2013
Q2 | $66K | Buy |
+1,866
| New | +$71.4K | ﹤0.01% | 6400 |
|
Other funds holding HBIO
WCM
VCM
CCM
MIM
NCNMGF
Bank of America's HBIO Position: Q1 2026 in Review
Bank of America sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 45 shares — an estimated $301 sold.
Bank of America first reported a position in HBIO in Q2 2013 and held it in 46 quarters. The position peaked at $2.12M in Q1 2019. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.
- Bank of America reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 45 Harvard Bioscience shares in Q1 2026, an estimated $301.
- Bank of America first reported a position in Harvard Bioscience in Q2 2013 and held it in 46 quarters.
- Bank of America's Harvard Bioscience position peaked at $2.12M in Q1 2019.
- 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.